Paradromics vs Tempus

Side-by-side comparison of AI visibility scores, market position, and capabilities

Tempus leads in AI visibility (74 vs 36)
Paradromics logo

Paradromics

EmergingLife Sciences & BioTech

Brain-Computer Interface (BCI) for Speech Restoration

Paradromics is developing the Connexus fully implantable BCI for speech restoration in paralyzed patients; received FDA IDE approval and completed first human implant at University of Michigan in May 2026;

AI VisibilityBeta
Overall Score
D36
Category Rank
#109 of 198
AI Consensus
74%
Trend
stable
Per Platform
ChatGPT
32
Perplexity
34
Gemini
31

About

Paradromics is a neurotechnology company based in Austin, Texas, focused on developing brain-computer interface (BCI) technology specifically for restoring communication and independence to patients with severe paralysis caused by ALS, stroke, and spinal cord injury. The company's lead product, the Connexus BCI, is a fully implantable neural interface system designed to record high-resolution neural signals from the motor cortex and decode them into speech output — enabling patients who have lost the ability to speak or move to communicate through their thoughts.

Full profile
Tempus logo

Tempus

LeaderLife Sciences & BioTech

AI-Enabled Precision Medicine

Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.

AI VisibilityBeta
Overall Score
B74
Category Rank
#11 of 198
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
71
Perplexity
68
Gemini
80

About

Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.

Full profile

AI Visibility Head-to-Head

36
Overall Score
74
#109
Category Rank
#11
74
AI Consensus
68
stable
Trend
stable
32
ChatGPT
71
34
Perplexity
68
31
Gemini
80
41
Claude
77
31
Grok
69

Key Details

Category
Brain-Computer Interface (BCI) for Speech Restoration
AI-Enabled Precision Medicine
Tier
Emerging
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.